In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp

Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro

(2010) Marina Muzza et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer

(2009) J P. Couto et al.   JOURNAL OF CLINICAL PATHOLOGY

RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR

(2008) M. Croyle et al.   CANCER RESEARCH

A Novel RET Kinase- -Catenin Signaling Pathway Contributes to Tumorigenesis in Thyroid Carcinoma

(2008) T. S. Gujral et al.   CANCER RESEARCH

Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement

(2008) Y. C. Henderson et al.   CLINICAL CANCER RESEARCH

Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.

(2008) Mario Colombo-Benkmann et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

(2008) Vandana Gupta-Abramson et al.   JOURNAL OF CLINICAL ONCOLOGY

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

(2008) Steven I. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE